Updated July 17, 2009
Approval triggers $12 million payment to BDSI. Product, called Onsolis, targets breakthrough cancer pain and is delivered through dissolvable patch.
Updated October 13, 2008
Niraj Vasisht is the new chief technical officer at BioDelivery Sciences International .
April 2, 2008
Meda AB Files for European Approval of BEMA™ Fentanyl
Updated January 15, 2008
Combination of narcotic, oral lozenge could be used to treat pain caused by other ailments beyond cancer.
Updated November 2, 2007
Move to larger space made to accommodate more employees, company says.
Updated November 1, 2007
Morrisville-based company seeks FDA approval for ‘breakthrough cancer pain.’ BDSI hopes to launch sales in 2008.
September 10, 2007
RTP-based firm buys all U.S. rights to oral delivery method from QLT USA.
Updated September 5, 2007
Europe-based Meda pays Morrisville drug development firm $30M up front for North America rights. Meda had already secured European rights.
Updated July 3, 2007
BioDelivery Sciences International announced Monday that its June 28 pre-NDA meeting with the U.S. Food and Drug Administration regarding the company’s Phase III BEMA Fentanyl product went according to plan.
April 26, 2007
Triangle-based drug development firm reports effectiveness in use of breakthrough pain killer.
Updated April 10, 2007
Al Medwar, who once worked for Triangle Pharmaceuticals, joins BDSI from EMD Pharmaceuticals.